» Articles » PMID: 33146844

Preclinical Models to Study Obesity and Breast Cancer in Females: Considerations, Caveats, and Tools

Overview
Date 2020 Nov 4
PMID 33146844
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Obesity increases the risk for breast cancer and is associated with poor outcomes for cancer patients. A variety of rodent models have been used to investigate these relationships; however, key differences in experimental approaches, as well as unique aspects of rodent physiology lead to variability in how these valuable models are implemented. We combine expertise in the development and implementation of preclinical models of obesity and breast cancer to disseminate effective practices for studies that integrate these fields. In this review, we share, based on our experience, key considerations for model selection, highlighting important technical nuances and tips for use of preclinical models in studies that integrate obesity with breast cancer risk and progression. We describe relevant mouse and rat paradigms, specifically highlighting differences in breast tumor subtypes, estrogen production, and strategies to manipulate hormone levels. We also outline options for diet composition and housing environments to promote obesity in female rodents. While we have applied our experience to understanding obesity-associated breast cancer, the experimental variables we incorporate have relevance to multiple fields that investigate women's health.

Citing Articles

Effects of follicle-stimulating hormone on energy balance and tissue metabolic health after loss of ovarian function.

Libby A, Solt C, Jackman M, Sherk V, Foright R, Johnson G Am J Physiol Endocrinol Metab. 2024; 326(5):E626-E639.

PMID: 38536037 PMC: 11208003. DOI: 10.1152/ajpendo.00400.2023.


FGFR1 Signaling Facilitates Obesity-Driven Pulmonary Outgrowth in Metastatic Breast Cancer.

Cotul E, Safdar M, Paez S, Kulkarni A, Ayers M, Lin H Mol Cancer Res. 2023; 22(3):254-267.

PMID: 38153436 PMC: 10923021. DOI: 10.1158/1541-7786.MCR-23-0955.


Unlocking Translational Potential: Conditionally Reprogrammed Cells in Advancing Breast Cancer Research.

Daneshdoust D, Luo M, Li Z, Mo X, Alothman S, Kallakury B Cells. 2023; 12(19).

PMID: 37830602 PMC: 10572051. DOI: 10.3390/cells12192388.


Diabetes mellitus in breast cancer survivors: metabolic effects of endocrine therapy.

Thomas N, Scalzo R, Wellberg E Nat Rev Endocrinol. 2023; 20(1):16-26.

PMID: 37783846 PMC: 11487546. DOI: 10.1038/s41574-023-00899-0.


FGF1 supports glycolytic metabolism through the estrogen receptor in endocrine-resistant and obesity-associated breast cancer.

Castillo-Castrejon M, Sankofi B, Murguia S, Udeme A, Cen H, Xia Y Breast Cancer Res. 2023; 25(1):99.

PMID: 37608351 PMC: 10463730. DOI: 10.1186/s13058-023-01699-0.


References
1.
Flegal K, Kruszon-Moran D, Carroll M, Fryar C, Ogden C . Trends in Obesity Among Adults in the United States, 2005 to 2014. JAMA. 2016; 315(21):2284-91. PMC: 11197437. DOI: 10.1001/jama.2016.6458. View

2.
Ogden C, Carroll M, Kit B, Flegal K . Prevalence of childhood and adult obesity in the United States, 2011-2012. JAMA. 2014; 311(8):806-14. PMC: 4770258. DOI: 10.1001/jama.2014.732. View

3.
Chan D, Vieira A, Aune D, Bandera E, Greenwood D, McTiernan A . Body mass index and survival in women with breast cancer-systematic literature review and meta-analysis of 82 follow-up studies. Ann Oncol. 2014; 25(10):1901-1914. PMC: 4176449. DOI: 10.1093/annonc/mdu042. View

4.
Neuhouser M, Aragaki A, Prentice R, Manson J, Chlebowski R, Carty C . Overweight, Obesity, and Postmenopausal Invasive Breast Cancer Risk: A Secondary Analysis of the Women's Health Initiative Randomized Clinical Trials. JAMA Oncol. 2015; 1(5):611-21. PMC: 5070941. DOI: 10.1001/jamaoncol.2015.1546. View

5.
Chen L, Cook L, Tang M, Porter P, Hill D, Wiggins C . Body mass index and risk of luminal, HER2-overexpressing, and triple negative breast cancer. Breast Cancer Res Treat. 2016; 157(3):545-54. PMC: 5575777. DOI: 10.1007/s10549-016-3825-9. View